Loading...
SCSC is not a good buy right now for an impatient buyer. Price is sitting near resistance with momentum getting stretched, the probabilistic near-term path skews negative (week/month), insiders are aggressively net selling, and an earnings event is imminent—better odds come either on a pullback (around ~41 or below) or after the earnings reset.
Trend/Momentum: MACD histogram is positive (0.195) and expanding, indicating upside momentum is still present; however RSI(6) is 68.6, approaching overbought, suggesting limited immediate upside before a pause/pullback. Levels: Current price 42.85 is above Pivot 41.112 and above R1 42.409, pushing into the 43.21 (R2) zone. That puts the stock close to resistance where breakouts can fail without fresh catalysts. Support sits near 41.11 first, then 39.82/39.01. Moving averages: Converging MAs implies a balance/transition regime (not a clean trend), consistent with a near-resistance stall risk. Quant pattern read-through: Similar-pattern projection shows +1.04% next day probability tilt, but -2.5% next week and -5.58% next month, which argues against chasing here.
Intellectia Proprietary Trading Signals

on 2026-02-05 pre-market: potential catalyst if results/guide beat expectations.
with RSI near overbought, increasing risk of a stall/pullback.
Latest reported quarter: 2026/Q1. Revenue fell to $739.65M (-4.63% YoY), but profitability improved: Net income $19.878M (+17.11% YoY) and EPS $0.89 (+28.99% YoY). Gross margin rose to 13.72 (+12.74% YoY). Overall: earnings/margins are trending better even as top-line growth is negative.
No analyst rating/price target change data was provided, so recent Wall Street upgrades/downgrades and target revisions cannot be confirmed here. Pros (what analysts typically like given the data): improving EPS and margins. Cons: declining revenue and heavy insider selling into the current price area. Influential/congress trading: no recent congress trading data available.
